Sun Pharma Advanced Research Company Limited has informed the Exchange about Investor Presentation

SPARC held an R&D Day on January 8, 2026, sharing updates on its narrowed pipeline focused on oncology and immunology. Two lead clinical programs are advancing ahead of schedule: SCD-153, a topical itaconate-based therapy for alopecia areata (Phase 1B ongoing in India, with interim readout expected in Q4 CY2026 and a global Phase 2 planned for Q2 CY2027), and SBO-154, a MUC1-targeting ADC for solid tumors (Phase 1 dose escalation underway in the US, Australia and India, now in cohort 3 at pharmacologically relevant doses). The company also highlighted a positive district court ruling on a pediatric rare disease voucher (PRV) with appeal window closing end-January, which could be worth over $100 million. Management outlined cost cuts reducing headcount from 400+ to around 250, delivering roughly $10 million in annual fixed cost savings on a ~$50 million base. SPARC is working on a funding plan to extend its cash runway to FY28, having already drawn $45 million+ in promoter-backed debt.